Conclusions: The current study suggests that telmisartan use in hypertensive T2DM patients may be associated with a lower risk of dementia and any IS events in an East-Asian population
Thus, telmisartan should be considered for putative treatment for subcortical vascular dementia, although strict monitoring of BP is required
Chi-Hung Liu, Pi-Shan Sung, Yan-Rong Li, Wen-Kuan Huang, Tay-Wey Lee, Chin-Chang Huang, Tsong-Hai Lee, Tien-Hsing
The risk of dementia diagnosis remained lower among telmisartan vs non-telmisartan recipients even
Clinical
Thus, telmisartan should be considered for putative treatment for subcortical vascular dementia, although strict monitoring of BP is required
022) or all-cause mortality as
The antihypertensive angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) have similar indications and mechanisms of action, but prior work suggests divergence in their effects on cognition
The patient have to talk with a doctor if such clinical problems exist as diabetes, heart disease The AT 1 antagonist telmisartan is an orally active, selective, biphenyl, nontetrazole, 6-substituted benzimidazole amino-peptide that has no apparent AT 1 agonist activity and does not interact with other receptors involved in cardiovascular regulation
Background: This was a prospective observational study done to observe the effects of telmisartan on cognitive function in hypertensive dementia patients
Puede ser tomado con o sin
Common side effects of telmisartan may include: stuffy nose, sinus pain; back pain; or
Telmisartan side effects (more detail) A Cleveland Clinic-led study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association showed that telmisartan, a drug currently prescribed for people with high blood pressure, is associated with a lower risk of Alzheimer’s specifically in Black patients over age 60
Comparison of the cumulative incidence of dementia between telmisartan and non-telmisartan angiotensin receptor blocker groups in the propensity-score-matched cohort
Telmisartan belongs to a group of medicines called angiotensin II receptor blockers
Cutaneous adverse drug reactions have been observed in 2%–3% of hospitalized patients
)
) streptozotocin (STZ) induced dementia of Alzheimer's disease (AD) type in mice